Cancer multitarget pharmacology in prostate tumors: tyrosine kinase inhibitors and beyond

M Bologna, C Vicentini, P Muzi, G Pace… - Current medicinal …, 2011 - ingentaconnect.com
Tyrosine kinase inhibitors are currently one of the most important classes of cancer drugs,
essentially because many kinases and regulators are molecules related to frequently …
被引用次数：18 相关文章

Cancer multitarget pharmacology in prostate tumors: tyrosine kinase inhibitors and beyond.

M Bologna, C Vicentini, P Muzi, G Pace… - Current Medicinal …, 2011 - europepmc.org
Cancer multitarget pharmacology in prostate tumors: tyrosine kinase inhibitors and beyond. -
Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu About …

Cancer multitarget pharmacology in prostate tumors: tyrosine kinase inhibitors and beyond

M Bologna, C Vicentini, P Muzi… - Current medicinal …, 2011 - pubmed.ncbi.nlm.nih.gov
Tyrosine kinase inhibitors are currently one of the most important classes of cancer drugs,
essentially because many kinases and regulators are molecules related to frequently …

[引用][C] Cancer Multitarget Pharmacology in Prostate Tumors: Tyrosine Kinase Inhibitors and Beyond: Protein kinases in cancer: recent findings

M BOLOGNA, C VICENTINI, P MUZI… - Current medicinal …, 2011 - pascal-francis.inist.fr
Cancer Multitarget Pharmacology in Prostate Tumors: Tyrosine Kinase Inhibitors and
Beyond : Protein kinases in cancer: recent findings CNRS Inist Pascal-Francis CNRS …

Cancer multitarget pharmacology in prostate tumors: tyrosine kinase inhibitors and beyond

M Bologna, C Vicentini, P Muzi, G Pace… - Current Medicinal …, 2011 - hero.epa.gov
Tyrosine kinase inhibitors are currently one of the most important classes of cancer drugs,
essentially because many kinases and regulators are molecules related to frequently …

[引用][C] Cancer Multitarget Pharmacology in Prostate Tumors: Tyrosine Kinase Inhibitors and Beyond

M BOLOGNA, C VICENTINI, P MUZI, G PACE… - Current medicinal …, 2011 - Bentham